Ghent University Academic Bibliography

Advanced

Maintaining the silence: reflections on long-term RNAi

Koen Raemdonck UGent, Roosmarijn Vandenbroucke UGent, Jo Demeester UGent, Niek Sanders UGent and Stefaan De Smedt UGent (2008) DRUG DISCOVERY TODAY. 13(21-22). p.917-931
abstract
Since the demonstration of RNA interference (RNAi) in mammalian cells, considerable research and financial effort has gone towards implementing RNAi as a viable therapeutic platform. RNAi is, without doubt, the most promising strategy for the treatment of human genetic disorders. Because many of the targets proposed for RNAi therapy require chronic treatment, researchers agree that the emphasis must now be placed on the safe and long-term application of RNAi drugs to reap the benefits at last.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
MAMMALIAN-CELLS, HUMAN-CELLS, DNA METHYLATION, SMALL INTERFERING RNA, SHORT HAIRPIN RNA, DOUBLE-STRANDED-RNA, IN-VIVO DELIVERY, TRANSMEMBRANE PROTEIN SID-1, INNATE IMMUNE-RESPONSE, HEPATITIS-B-VIRUS
journal title
DRUG DISCOVERY TODAY
Drug Discov. Today
volume
13
issue
21-22
pages
917 - 931
Web of Science type
Review
Web of Science id
000261086400003
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
6.618 (2008)
JCR rank
15/216 (2008)
JCR quartile
1 (2008)
ISSN
1359-6446
DOI
10.1016/j.drudis.2008.06.008
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
446726
handle
http://hdl.handle.net/1854/LU-446726
date created
2009-01-15 13:41:00
date last changed
2011-05-05 09:59:49
@article{446726,
  abstract     = {Since the demonstration of RNA interference (RNAi) in mammalian cells, considerable research and financial effort has gone towards implementing RNAi as a viable therapeutic platform. RNAi is, without doubt, the most promising strategy for the treatment of human genetic disorders. Because many of the targets proposed for RNAi therapy require chronic treatment, researchers agree that the emphasis must now be placed on the safe and long-term application of RNAi drugs to reap the benefits at last.},
  author       = {Raemdonck, Koen and Vandenbroucke, Roosmarijn and Demeester, Jo and Sanders, Niek and De Smedt, Stefaan},
  issn         = {1359-6446},
  journal      = {DRUG DISCOVERY TODAY},
  keyword      = {MAMMALIAN-CELLS,HUMAN-CELLS,DNA METHYLATION,SMALL INTERFERING RNA,SHORT HAIRPIN RNA,DOUBLE-STRANDED-RNA,IN-VIVO DELIVERY,TRANSMEMBRANE PROTEIN SID-1,INNATE IMMUNE-RESPONSE,HEPATITIS-B-VIRUS},
  language     = {eng},
  number       = {21-22},
  pages        = {917--931},
  title        = {Maintaining the silence: reflections on long-term RNAi},
  url          = {http://dx.doi.org/10.1016/j.drudis.2008.06.008},
  volume       = {13},
  year         = {2008},
}

Chicago
Raemdonck, Koen, Roosmarijn Vandenbroucke, Jo Demeester, Niek Sanders, and Stefaan De Smedt. 2008. “Maintaining the Silence: Reflections on Long-term RNAi.” Drug Discovery Today 13 (21-22): 917–931.
APA
Raemdonck, K., Vandenbroucke, R., Demeester, J., Sanders, N., & De Smedt, S. (2008). Maintaining the silence: reflections on long-term RNAi. DRUG DISCOVERY TODAY, 13(21-22), 917–931.
Vancouver
1.
Raemdonck K, Vandenbroucke R, Demeester J, Sanders N, De Smedt S. Maintaining the silence: reflections on long-term RNAi. DRUG DISCOVERY TODAY. 2008;13(21-22):917–31.
MLA
Raemdonck, Koen, Roosmarijn Vandenbroucke, Jo Demeester, et al. “Maintaining the Silence: Reflections on Long-term RNAi.” DRUG DISCOVERY TODAY 13.21-22 (2008): 917–931. Print.